Kornimate/medical-research-clean huggingface dataset:
azilect + antidepressant chart review

Conditions: Serotonin Syndrome

Summary: to identify the occurrence of serotonin toxicity in parkinson's disease (pd) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to pd patients receiving antidepressants, but not rasagiline.


Eligibility criteria:
inclusion criteria: 1. male or female patients with a diagnosis of pd 2. rasagiline treatment as mono- or adjunct therapy for pd with concomitant antidepressant medication (ssris, snris, st. john's wort and/or tcas) at any time during the specified review period, or rasagiline treatment as mono- or adjunct therapy for pd without concomitant antidepressant medication (ssris, snris, st. john's wort and/or tcas) at any time during the specified review period. or antidepressant therapy (ssris, snris, st. john's wort and/or tcas) and any other dopaminergic anti-pd treatment besides rasagiline or selegiline at any time during the specified review period 3. willing to consent to review of office chart and to review of records of er visits and/or hospitalizations corresponding to the review window, if required 4. patients previously participating in a rasagiline clinical trial (and their follow-up protocols) are eligible, provided that they did not receive antidepressant therapy during trial participation. 5. in addition to the above criteria, each group has specific inclusion criteria stated below: * group r+ad: enrollment in this group requires that patients must have taken rasagiline and an antidepressant (ssris, snris, st. john's wort and/or tcas, regardless of indication) within 14 days of each other (or five weeks, if fluoxetine preceded rasagiline). * group r: enrollment in this group requires patients must have at least 2 months of rasagiline use. * group ad: patients must be taking an approved dopaminergic medication for pd. enrollment in this group requires that patients must have at least 2 months of treatment with an antidepressant medication. exclusion criteria: 1. use of rasagiline for any indication other than pd 2. patients taking a monoamine oxidase inhibitor (maoi) antidepressant and/or selegiline 3. inability or unwillingness to request records of er visits and/or hospitalizations corresponding to the review period.

Keywords: parkinson's disease serotonin toxicity rasagiline antidepressants chart review retrospective
housing and health study

Conditions: HIV; AIDS

Summary: the goal of the project is to examine the impact of providing housing for people living with hiv who are homeless or at imminent risk of homelessness on their hiv disease progression, risks of transmitting hiv, and medical care access and utilization.

evidence is accumulating that homelessness and housing may be important factors that influence human immunodeficiency virus (hiv) sex and drug risk behaviors. despite this apparent connection, few studies have investigated whether homelessness or unstable housing, compared with stable and adequate housing, is linked with hiv risk behaviors, and whether change in housing status is associated with change in risk behaviors. the housing and health study is a multi-site, multi-agency research collaboration. this project is a unique collaboration between federal agencies (the department of housing and urban development and the centers for disease control and prevention), local government agencies, universities, and private not-for-profit organizations. the goal of the project is to examine the impact of providing housing for people living with hiv who are homeless or at imminent risk of homelessness on their disease progression, their risks of transmitting hiv, and medical care access and utilization. a total of 630 people living with hiv from three study sites complete the baseline study sessions. half the participants (n=315) are randomly assigned to each of the two study groups. treatment group participants receive housing and health study housing rental assistance, and comparison group participants receive assistance finding housing according to local standard practice. at baseline, 6, 12, and 18 months after baseline, participants complete study questionnaires and provide blood specimens to test for cd4 and viral load. in addition, the cost effectiveness of the study will be investigated by examining the hiv-related costs averted by providing housing to persons at high risk for transmitting hiv.

Eligibility criteria:
inclusion criteria: * hiv seropositive * at least 18 years of age * english or spanish speaking * able to provide informed consent * able to participate in data collection protocol * categorized as low income (less than 80% of the area median income) * homeless or at imminent risk of homelessness * able to provide information about identity exclusion criteria: -

Keywords: hiv aids homeless homelessness housing hiv seropositive hiv risk behavior
stereotactic radiation in vestibular schwannoma

Conditions: Vestibular Schwannoma

Summary: the purpose of this study is to determine whether stereotactic radiosurgery (srs)and stereotactic radiotherapy (srt)are effective in the treatment of vestibular schwannoma (vs).

vestibular schwannomas (vss) are slow-growing tumors of the myelin-forming cells that cover cranial nerve viii.the treatment options for patients with vss include active observation, surgical management, and radiotherapy. however, the optimal treatment choice remain controversial. over the past 10 years, there has been rapid progress in the application of stereotactic radiotherapy to the treatment of vss. the stereotactic radiotherapy program includes single fraction radiosurgery (srs) and hypofraction stereotactic radiotherapy (hsrt) are commonly used for vss treatment. since srs and srt techniques differ significantly enough to raise questions of therapeutic advantage and until now, there is no prospective, randomized study comparing the outcomes for patients treated using both radiotherapy techniques. we designed the first prospective randomized protocol to compare srs and srt for answer this question.

Eligibility criteria:
inclusion criteria: * vestibular schwannoma tumor size not more than 3 cm. exclusion criteria: * nf 2 patient * underlying cerebrovascular disease * tumor compress and efface brain stem ( koos 4)

Keywords: stereotactic radiotherapy srs srt vestibular schwannoma
next-generation sequencing for pathogen detection and quantification in children with musculoskeletal infections

Conditions: Musculoskeletal Infection; Acute Hematogenous Osteomyelitis; Septic Arthritis; Osteomyelitis; Pyomyositis

Summary: the purpose of this study is to evaluate the use of a blood test: karius® plasma-based next-generation sequencing test (karius test), to see if we can detect and measure the infection causing agent in children with musculoskeletal infections (mski).

children admitted to riley hospital for children (rhc) with musculoskeletal infections (osteomyelitis, septic arthritis, or pyomyositis) over a 12-month period will be prospectively enrolled. eligible subjects will be identified by referral from the infectious diseases and orthopedic services at rhc. blood samples will be obtained on the day of admission (within 48hrs), and 24 hours after the admission sample for real-time ngs (next-generation sequencing) testing at karius laboratory (redwood city, ca). if a pathogen is identified by ngs, in either of the first two samples, subsequent samples will be sent every 48-72 hours while inpatient, and then collected every 1-2 weeks after hospital discharge, while being treated for mski (maximum 3 follow-up samples). if both of the initial inpatient ngs samples are negative, no further samples will be sent for ngs. pathogen identification by ngs will be compared to standard cultures methods, and quantitative cfdna (cell-free dna) will be evaluated over time.

Eligibility criteria:
inclusion criteria: 1. 6 months (to ensure adequate blood volume drawn) to 18 years of age. 2. strong clinical suspicion of mski as evidenced by fever, osteoarticular pain (e.g. tenderness to palpation of a joint, bone pain, or refusal to bear weight); and elevated esr (erythrocyte sedimentation rate) or crp (c-reactive protein). exclusion criteria: * subjects will be excluded if they have clinical evidence suggesting an alternative diagnosis; inability or unwillingness to consent for the study

Keywords: infection plasma based next generation sequencing blood culture tissue culture joint fluid culture pathogen identification
interleukin-6 in plaque psoriasis and its possible role in disease severity

Conditions: Interleukin-6; Plaque Psoriasis; Disease Severity

Summary: this study aimed to evaluate serum il-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.

psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population. interleukin (il)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. it is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. increased il-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis

Eligibility criteria:
inclusion criteria: * age above 18 years. * both sexes. * patients clinically diagnosed with plaque psoriasis. exclusion criteria: * patients who had received any treatment for psoriasis in the last three months. * patients with other types of psoriasis. * those currently receiving systemic treatment. * individuals with other inflammatory diseases. * pregnant or lactating women. * those using contraceptive pills. * patients with metabolic conditions like diabetes mellitus or thyroid disorders.
evaluation of simplified antiretroviral treatment strategies in hiv infected children treated by antiretroviral (arv) before one year of age

Conditions: HIV Infections

Summary: the monod trial aim to evaluate the implementation of early antiretroviral treatment strategies in hiv-infected infants and assess the feasibility and efficacy of simplifying the initial proposed regimen after a successful one year treatment. the initial treatment is azt-3tc-lpv/r twice a day. after one year, the children will be randomized in one of the following : arm 1-reference azt-3tc-lpv/r twice daily; arm 2-simplified abc-3tc-efv once daily. the perspective of this project is to identify antiretroviral strategies to improve treatment access and adherence for children in sub-saharian africa.


Eligibility criteria:
inclusion criteria for antiretroviral treatment initiation: * infant follow-up in one of the trial site * hiv-1 infection diagnose by rt pcr after 6 weeks of life * age between 3 and 12 month at the antiretroviral treatment initiation * naive of antiretrovirals except if received for the prevention of mother to child hiv transmission * hb\>=7 g/dl, neutrophiles\>750/mm3, creatinin\<3xuln, tgo and tgp\<3xuln * signed informed consent exclusion criteria for antiretroviral treatment initiation: * hiv-2 infection or hiv-1/hiv-2 co-infection * known intolerance to one of the trial treatment * hb\ 3xuln, tgo or tgp\>3xuln inclusion criteria for randomisation at 12 months in the simplification phase: * age 24 months at most * virological success define as 2 consecutive indetectable hiv rna measured by rt pcr at least 3 months apart. exclusion criteria for randomisation at 12 months in the simplification phase: * virological failure after the first 12 months of antiretroviral treatment

Keywords: hiv antiretroviral therapy infant sub saharian africa
achieve: optimizing the treatment of secondary hyperparathyroidism

Conditions: Secondary Hyperparathyroidism

Summary: the purpose of this study is to compare the proportion of chronic kidney disease (ckd) subjects on dialysis receiving sensipar® and low dose vitamin d or escalating doses of vitamin d alone who are able to achieve the national kidney foundation-kidney disease outcomes quality initiative (nkf-k/doqi) secondary hyperparathyroidism (hpt) treatment targets for both biointact parathyroid hormone (bipth) and calcium-phosphorus (ca x p) product.


Eligibility criteria:
inclusion criteria: - on hemodialysis for at least 3 months and have received intravenous vitamin d therapy (paricalcitol or doxercalciferol) for at least 3 months prior to entering screening - historical ipth 150-800 pg/ml (or bipth 80-430 pg/ml) within 6 months and corrected serum ca greater than 8.4 mg/dl within 2 months prior to screening period. for subjects with bipth 80-160 pg/ml (ipth 150-300 pg/ml), ca x p must be greater than 55 mg²/dl² within 2 months prior to the screening period - screening (pre-washout) bipth 80-430 pg/ml and a corrected serum ca level greater than 8.4 mg/dl. for subjects with bipth 80-160 pg/ml ca x p must be also greater than 55 mg²/dl² - baseline mean bipth (post-washout) greater than 160 pg/ml and mean corrected ca greater than 8.4 mg/dl exclusion criteria: - parathyroidectomy in the 3 month period prior to screening - current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets - use of investigational drug or device or participation in a trial of investigational drug or device within 30 days of screening - females of child bearing potential who are pregnant (e.g., positive pregnancy test) or are breast feeding or who refuse to use highly effective contraceptive measures (as determined by the investigator) throughout the study - previously participated in this or any other sensipar® study or has received or is receiving sensipar® as a commercially available product

Keywords: vitamin d sensipar® cinacalcet hcl chronic kidney disease
study of the safety of use of intravitreal sok583a1 provided in a vial kit

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Summary: this is a single-arm, open-label study where all patients will receive a single injection of sok583a1 (40 mg/ml) provided in a vial kit at baseline. the total study duration for the individual participant is approximately 31 days.

subjects with namd received a single dose of study treatment (2 mg sok583 in 0.05 ml) in line with the eylea uspi, which recommends a dose of 2 mg aflibercept (0.05 ml) administered by ivt injection. only subjects already under ivt eylea treatment and hence familiar with the ivt procedure were eligible for the study. administration of the study treatment was embedded into their routine treatment scheme.

Eligibility criteria:
inclusion criteria: * patients ≥ 50 years of age at baseline * patients diagnosed with namd (uni- or bilateral) * patients already under ivt eylea treatment (last injection of the induction period or maintenance phase) * willing and able to comply with all study procedures, and be likely to complete the study * signed informed consent must be obtained before any assessment is performed exclusion criteria: * active, suspected or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or autoimmune associated uveitis or endophthalmitis * any uncontrolled ocular hypertension or glaucoma in the study eye (defined as iop ≥ 26 mmhg, despite treatment with anti-glaucomatous medication) * history of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of investigational product * visual acuity score (vas) worse than 20/200 on a snellen chart, the generally accepted level of legal blindness * topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening * systemic treatment with long-acting corticosteroids (more than 10 mg prednisolone equivalent) within 3 months prior to screening current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol * any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye any time during the past 3 months * receipt of any systemic anti-vegf within the last 6 months prior to enrollment * uncontrolled hypertension (defined as a systolic value ≥ 160 mmhg or diastolic value ≥ 100 mmhg at screening) * participants who do not comply with the local covid-19 regulations of the study site

Keywords: open label study, intravitreal injection, biosimilar, aflibercept, vial kit
pre-emptive prevention for patients at high risk for hospital-onset clostridioides difficile

Conditions: C. Difficile

Summary: clostridioides difficile (c. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the us. traditional approaches to reduce hospital-onset cdi focus on identifying, isolating, and treating symptomatic patients to prevent transmission to other patients. recent genomic epidemiology studies, however, suggest that most hospital-onset cdi cases are attributable to asymptomatic carriers who either progress from colonization to active infection themselves or transmit c. difficile to other patients while asymptomatic. this trial will evaluate an intervention to pre-emptively identify asymptomatic c. difficile carriers and then implement a patient-tailored prevention package to protect the carrier from progression to active infection and to prevent transmission from the carrier to other patients.


Eligibility criteria:
inclusion criteria: * patients admitted to icu or oncology units and identified to carry c. difficile via vre swab exclusion criteria: * patients not identified as carriers of c. difficile and patients not admitted to icu or oncology units

Keywords: prevention hospital-acquired infection
the study of association between intradialysis sodium balance and clinical outcomes in chronic hemodialysis patients

Conditions: End-stage Renal Disease

Summary: the purpose of this study is to determine whether the change of serum and dialysate sodium level during hemodialysis can influence on blood pressure and intradialytic weight gain in chronic hemodialysis patients.


Eligibility criteria:
inclusion criteria: * age 20 years or more * hemodialysis vintage over 3 months * dialyzed for 4 hours three times per week * hemodialysis adequacy (kt/v) over 1.2 exclusion criteria: * diagnosed with chronic hepatitis or infection
high altitude (ha) residents with high altitude pulmonary hypertension (haph), pulmonary artery pressure (pap) assessed at ha (3200 m) vs la (760 m)

Conditions: High Altitude Pulmonary Hypertension

Summary: to study the effect of relocation from 3200 m (aksay) to 760 m (bishkek) in patients with high altitude pulmonary hypertension (haph) who permanently live \>2500 m on pulmonary artery pressure (pap)

this research in highlanders with haph diagnosed by echocardiography and defined by a rv/ra \>30 mmhg who permanently live at ha \>2500 m will have pulmonary arterial pressure (pap) assessed by echocardiography near their living altitude in aksay at 3200 m and at 760 m in bishkek the day after the first and the seventh night after relocation.

Eligibility criteria:
inclusion criteria: * permanently living \>2500 m * haph diagnosed with a minimum rv/ra of 30 mmhg assessed by echocardiography at an altitude of 3200 m * written informed consent exclusion criteria: * highlanders who cannot follow the study investigations, * patients with moderate to severe concomitant lung disease (fev1\ 20 cigarettes/day or \>20 pack-years. * coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Keywords: pulmonary hypertension hypoxia high altitude pulmonal arterial pressure
efficacy at 24 weeks and safety, tolerability and long term efficacy of secukinumab (ain457) in patients with active rheumatoid arthritis (ra) and an inadequate response to anti-tumor necrosis factor α (anti-tnfα) agents (cain457f2309 and cain457f2309e1)

Conditions: Rheumatoid Arthritis

Summary: the core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-tnf-α agents. patients received either secukinumab, placebo or abatacept (active comparator). the core study was completed. however, the extension study was prematurely terminated after the primary endpoint analysis of the core study at week 24 had demonstrated numerically higher efficacy for the active comparator abatacept compared to secukinumab.


Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating female patients * presence of ra classified by acr 2010 revised criteria for at least 3 months before screening * at baseline: disease activity criteria defined by \>= 6 tender joints out of 68 and \>= 6 swollen joints out of 66 with at least 1 of the following at screening: * anti-cyclic citrullinated peptide (anti-ccp) antibodies positive or * rheumatoid factor positive and with at least 1 of the following at screening: * high sensitivity c-reactive protein (hscrp) \>= 10 mg/l or * erythrocyte sedimentation rate (esr) \>= 28 millimeter (mm)/1st hour * patients must have been taking at least one anti-tnf-α agent given at an approved dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one administration of an anti-tnf-α agent * patients must be taking mtx or any other dmard (but not more than 1 dmard) for at least 3 months before randomization and have to be on a stable dose at least 4 weeks before randomization (7.5 to 25 mg/week for mtx or other dmard at maximum tolerated dose) exclusion criteria: * chest x-ray with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician * ra patients functional status class iv according to the acr 1991 revised criteria * patients who have ever received biologic immunomodulating agents except for those targeting tnfα * previous treatment with any cell-depleting therapies other protocol-defined inclusion/exclusion criteria may apply.

Keywords: rheumatoid arthritis ra acr inflammatory joints
characteristic analysis and surgical exploration for acetabular roof fractures: multicenter retrospective cohort study

Conditions: Acetabular Fracture

Summary: acetabular roof was a crucial structure for maintaining the stability of hip joint; however, its important role was not especially emphasized in the letournel-judet classification system. acetabular roof was segmented into the roof column and roof wall in three-column classification and fracture in this area alone was defined as a3 injury. radiographic data and functional outcome of a3 injury patients were reviewed to explore the characteristics and surgical strategy.

fracture data, surgical incision, operation time, blood loss, fracture healing， reduction quality，functional outcome，and relevant complications

Eligibility criteria:
inclusion criteria: * 18-80 years, acute (\<14 days) closed roof column/wall acetabular fractures (a3.1, a3.2 or a3.3) in three-column classification, normal activity of the affected hip before the injury, received surgical reduction and internal fixation exclusion criteria: * open fractures, pathologic fractures, limited range of motion (rom) of the hip joint before the injury, conservative treatment, risk factors affecting bone healing (such as smoking and metabolic diseases) and noncompletion of the two-year follow-up